RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation by Vucur, Mihael et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis
by controlling caspase-8- and JNK-dependent compensatory cell proliferation
Vucur, Mihael; Reisinger, Florian; Gautheron, Jérémie; Janssen, Joern; Roderburg, Christoph;
Cardenas, David Vargas; Kreggenwinkel, Karina; Koppe, Christiane; Hammerich, Linda; Hakem, Razq;
Unger, Kristian; Weber, Achim; Gassler, Nikolaus; Luedde, Mark; Frey, Norbert; Neumann, Ulf Peter;
Tacke, Frank; Trautwein, Christian; Heikenwalder, Mathias; Luedde, Tom
Abstract: For years, the term ”apoptosis” was used synonymously with programmed cell death. However,
it was recently discovered that receptor interacting protein 3 (RIP3)-dependent ”necroptosis” represents
an alternative programmed cell death pathway activated in many inflamed tissues. Here, we show in a
genetic model of chronic hepatic inflammation that activation of RIP3 limits immune responses and com-
pensatory proliferation of liver parenchymal cells (LPC) by inhibiting Caspase-8-dependent activation of
Jun-(N)-terminal kinase in LPC and nonparenchymal liver cells. In this way, RIP3 inhibits intrahepatic
tumor growth and impedes the Caspase-8-dependent establishment of specific chromosomal aberrations
that mediate resistance to tumor-necrosis-factor-induced apoptosis and underlie hepatocarcinogenesis.
Moreover, RIP3 promotes the development of jaundice and cholestasis, because its activation suppresses
compensatory proliferation of cholangiocytes and hepatic stem cells. These findings demonstrate a func-
tion of RIP3 in regulating carcinogenesis and cholestasis. Controlling RIP3 or Caspase-8 might represent
a chemopreventive or therapeutic strategy against hepatocellular carcinoma and biliary disease.
DOI: https://doi.org/10.1016/j.celrep.2013.07.035
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-86692
Veröffentlichte Version
 
 
Originally published at:
Vucur, Mihael; Reisinger, Florian; Gautheron, Jérémie; Janssen, Joern; Roderburg, Christoph; Cardenas,
David Vargas; Kreggenwinkel, Karina; Koppe, Christiane; Hammerich, Linda; Hakem, Razq; Unger, Kris-
tian; Weber, Achim; Gassler, Nikolaus; Luedde, Mark; Frey, Norbert; Neumann, Ulf Peter; Tacke, Frank;
Trautwein, Christian; Heikenwalder, Mathias; Luedde, Tom (2013). RIP3 inhibits inflammatory hepato-
carcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell
proliferation. Cell Reports, 4(4):776-790.
DOI: https://doi.org/10.1016/j.celrep.2013.07.035
Cell Reports
Article
RIP3 Inhibits Inflammatory Hepatocarcinogenesis
but Promotes Cholestasis by Controlling Caspase-8-
and JNK-Dependent Compensatory Cell Proliferation
Mihael Vucur,1,11 Florian Reisinger,5,11 Je´re´mie Gautheron,1,2,11 Joern Janssen,1 Christoph Roderburg,1
David Vargas Cardenas,1 Karina Kreggenwinkel,1 Christiane Koppe,1 Linda Hammerich,1 Razq Hakem,7 Kristian Unger,6
AchimWeber,8 Nikolaus Gassler,3 Mark Luedde,9 Norbert Frey,9 Ulf Peter Neumann,4 Frank Tacke,1 Christian Trautwein,1
Mathias Heikenwalder,5,10 and Tom Luedde1,*
1Department of Medicine III
2Interdisciplinary Centre for Clinical Research (IZKF)
3Institute of Pathology
4Department of Visceral and Transplantation Surgery
University Hospital RWTH Aachen, D-52074 Aachen, Germany
5Institute of Virology, Helmholtz Zentrum Mu¨nchen fu¨r Gesundheit und Umwelt (HMGU), D-81675 Munich, Germany
6Research Unit of Radiation Cytogenetics, Helmholtz-Zentrum Mu¨nchen fu¨r Gesundheit und Umwelt (HMGU), D-85764 Neuherberg,
Germany
7Departments of Medical Biophysics and Immunology, Ontario Cancer Institute, University of Toronto, Toronto, ON M5G 2C1, Canada
8Institute of Surgical Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland
9Department of Cardiology and Angiology, University Hospital Kiel, D-24105 Kiel, Germany
10Institute of Virology, Technische Universita¨t Mu¨nchen (TUM), D-81675 Munich, Germany
11These authors contributed equally to this work
*Correspondence: tluedde@ukaachen.de
http://dx.doi.org/10.1016/j.celrep.2013.07.035
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are
credited.
SUMMARY
For years, the term ‘‘apoptosis’’ was used synony-
mously with programmed cell death. However, it
was recently discovered that receptor interacting
protein 3 (RIP3)-dependent ‘‘necroptosis’’ repre-
sents an alternative programmed cell death pathway
activated in many inflamed tissues. Here, we show in
a genetic model of chronic hepatic inflammation that
activation of RIP3 limits immune responses and
compensatory proliferation of liver parenchymal
cells (LPC) by inhibiting Caspase-8-dependent
activation of Jun-(N)-terminal kinase in LPC and non-
parenchymal liver cells. In this way, RIP3 inhi-
bits intrahepatic tumor growth and impedes the
Caspase-8-dependent establishment of specific
chromosomal aberrations that mediate resistance
to tumor-necrosis-factor-induced apoptosis and un-
derlie hepatocarcinogenesis. Moreover, RIP3 pro-
motes the development of jaundice and cholestasis,
because its activation suppresses compensatory
proliferation of cholangiocytes and hepatic stem
cells. These findings demonstrate a function of
RIP3 in regulating carcinogenesis and cholestasis.
Controlling RIP3 or Caspase-8 might represent a
chemopreventive or therapeutic strategy against
hepatocellular carcinoma and biliary disease.
INTRODUCTION
Hepatocellular carcinoma (HCC), themost common primary liver
tumor, arises almost exclusively in a setting of chronic hepatic
inflammation (Sherman, 2010). However, the knowledge on the
clear association between inflammation and cancer has not yet
translated into a chemopreventive pharmacological strategy
against HCC development, underlining the need for a better
understanding of molecular processes controlling the transition
from inflammation to cancer. Cell death represents a dominant
trigger for inflammation, thus contributing to multiple hallmark
capabilities of cancer (Hanahan and Weinberg, 2011). In chronic
liver disease, hepatocyte cell death is a prominent feature
driving progression to hepatic fibrosis and finally HCC (Zhang
and Friedman, 2012).
For years, the term apoptosis was used synonymously for
programmed cell death, whereas necrosis was considered a
passive, not specifically regulated, and ATP-independent
process (Chakraborty et al., 2012). Apoptosis is triggered by
ligation of death receptors, like tumor necrosis factor (TNF)
receptor, by their cognate ligands and represents a highly
synchronized procedure depending on activation of aspartate-
specific proteases, known as caspases (Chakraborty et al.,
2012). In viral hepatitis, immune cell-triggered apoptosis of
virally infected hepatocytes represents a key step in viral
clearance (Fung et al., 2009). Moreover, apoptotic death of
hepatocytes is a common feature of alcoholic and nonalcoholic
steatohepatitis and is associated with fibrosis (Feldstein and
Gores, 2005).
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It was recently discovered that, next to apoptosis, necropto-
sis—programmed necrosis depending on the kinases receptor
interacting protein 1 (RIP1) and RIP3—represents an alternative
programmed cell-death pathway downstream of the TNF-recep-
tor (Cho et al., 2009; He et al., 2009; Zhang et al., 2009). It can be
induced by viral infection and can serve as an alternative when
caspase-dependent apoptosis is inhibited or absent (Han
et al., 2011). Necroptosis plays a role in the regulation of chronic
inflammation in the pancreas, gut, and skin (Bonnet et al., 2011;
He et al., 2009; Welz et al., 2011). In human patients, necroptosis
is activated in alcoholic liver injury (Roychowdhury et al., 2013)
as one of the leading causes of liver cirrhosis and HCC in the
western world (Sherman, 2010). However, the functional role of
RIP3 in controlling the consequences of chronic inflammation
in the liver and other organs is presently not known. In this study,
we examined the role of RIP3 in a model of inflammatory hepa-
tocarcinogenesis based on conditional deletion of the mitogen-
activated protein 3 (MAP3)-kinase transforming growth factor
b (TGF-b)-activated-kinase-1 (TAK1) in liver parenchymal cells
(LPC) (TAK1LPC-KO) (Bettermann et al., 2010).
RESULTS
RIP3 Is Activated in TAK1-Deficient Livers andPromotes
Jaundice and Cholestasis by Inhibiting a Sufficient
Ductular Reaction
Mice with conditional deletion of Tak1 in LPC (TAK1LPC-KO mice)
display severe hepatic inflammation at a young age character-
ized by spontaneous LPC apoptosis and LPCnecrosis, proceed-
ing over time to liver fibrosis and liver cancer but also to severe
lethal cholestasis (Bettermann et al., 2010). In order to investigate
the function of RIP3 in hepatocarcinogenesis, we generated
mice with ablation of TAK1 in LPC together with a full knockout
of Rip3 (TAK1LPC-KO/RIP3/) or combined ablations of TAK1
and Caspase-8 in LPC (TAK1/Casp-8LPC-KO) and first compared
their phenotypes with wild-type (WT) and TAK1 single mutant
mice (TAK1LPC-KO) at the age of 6 weeks (Figure 1A).
We detected strongly increased protein levels of RIP3 in liver
extracts from TAK1LPC-KO and TAK1/Casp-8LPC-KO mice (Fig-
ure 1A), suggesting that LPC in these mice might be sensitized
to necrosis (He et al., 2009). Measurements of serum enzymes
from 6-week-old male mice confirmed that TAK1LPC-KO mice
showed a strong rise in serum aminotransferases (alanine
aminotransferase [ALT] and aspartate aminotransferase [AST])
and serum glutamate dehydrogenase (GLDH) levels compared
to WT mice as marker for hepatitis and LPC damage (Figure 1B).
Macroscopic analysis revealed that this coincided with yellow
color of livers and elevated serum bilirubin and alkaline phospha-
tase (AP) levels (Figures 1B and 1C), reflecting severe jaundice
and cholestasis as shown previously by electron-microscopical
analysis of bile canaliculi in TAK1LPC-KO animals (Bettermann
et al., 2010). Moreover, TAK1LPC-KO livers displayed macroscop-
ically visible nodules on the surface of livers (Figure 1C). Deletion
of Caspase-8 in TAK1LPC-KO mice led to significant reduction
in ALT, AST, and GLDH serum levels, and disappearance of
macroscopic nodules on the surface of liver lobes compared
to TAK1LPC-KO mice. However, no rescue in hyperbilirubinemia
and AP elevation was found (Figures 1B and 1C). In contrast,
deletion of Rip3 in TAK1LPC-KO mice led to a normalization of
bilirubin and reduced AP levels but worsened hepatitis, indicated
by significantly elevated ALT and GLDH levels in TAK1LPC-KO/
RIP3/ mice compared to TAK1LPC-KO animals (Figure 1B).
Moreover, while at 6 weeks of age, TAK1LPC-KO/RIP3/ livers
lacked a yellow color as a sign of jaundice; they displayed
multiple small nodules on their surface (Figure 1C).
Histological analysis of liver sections from 6-week-old male
mice revealed that jaundice in TAK1LPC-KO mice correlated with
the presence of areas of hepatocyte necrosis, which were
detected even to a higher extent in TAK1/Casp-8LPC-KO animals,
whereas necrosiswas absent in TAK1LPC-KO/RIP3/mice at this
age (Figures 2A and 2B). In parallel to the absence of necrosis,
TAK1LPC-KO/RIP3/ mice showed a strong ductular reaction
with expansion of A6+ (oval) cells (Figures 2A–2D), likely reflecting
a necessary process to maintain biliary homeostasis in a setting
of chronic inflammation (Desmet, 2011; Glaser et al., 2009). Strik-
ingly, this ductular reaction was absent in TAK1LPC-KO and TAK1/
Casp-8LPC-KOmice (Figures 2A, 2C, and 2D). These data demon-
strate that, in chronic hepatitis, Caspase-8-dependent apoptosis
primarily causes elevation of free circulating aminotransferases
and GLDH in the serum. In contrast, RIP3-dependent necropto-
sis promotes jaundice and cholestasis in TAK1LPC-KO livers,
because it is not linked with a ductular reaction.
Activation of RIP3 Limits Compensatory Proliferation
of Hepatocytes and Biliary Epithelial Cells in the
Chronically Inflamed Liver
We further analyzed the influence of RIP3 and Caspase-8 on
cell death in TAK1LPC-KO animals. In line with previous findings
(Bettermann et al., 2010), TAK1LPC-KO mice displayed significant
spontaneous LPC apoptosis as shown by immunohistochem-
istry and western blot analyses for cleaved Caspase-3 (Figures
3A–3C). Additional deletion of Caspase-8 resulted in complete
inhibition of Caspase-3 cleavage, whereas additional deletion
of Rip3 in TAK1LPC-KO mice resulted in a significant increase
in Caspase-3 cleavage when compared to TAK1LPC-KO mice
(Figures 3A–3C). Therefore, Caspase-8-dependent apoptosis
and RIP3-dependent necroptosis counterbalance and compete
with each other in the regulation of LPC death in TAK1LPC-KO
livers (compare Figures 2A and 2B and Figures 3A–3C).
We next examined the functions of Caspase-8 and RIP3 in
LPC proliferation in Tak1-deficient livers. Ki67 staining and west-
ern blot analyses of the cell cycle proteins proliferating cell nu-
clear antigen (PCNA) and cyclin D1 confirmed a high proportion
of proliferating LPC in TAK1LPC-KO mice (Figures 3A–3C). Addi-
tional deletion of Caspase-8 dramatically reduced the number
of proliferating LPC and the degree of PCNA/cyclin D1 expres-
sion, whereas proliferation remained high or was even higher
by tendency in mice with combined deletions of Tak1 and Rip3
(Figures 3A–3C). This indicates that Caspase-8-dependent
LPC apoptosis induces strong compensatory proliferation of
other adjacent LPC, which is not the case in terms of LPC
necroptosis. Interestingly, not only hepatocytes but also
biliary cells in TAK1LPC-KO/RIP3/ mice displayed increased
apoptosis and proliferation, as indicated by costainings for
pancytokeratin and Ki67 or cleaved Caspase-3 (Figures 3D–
3F). Thus, differential degrees of compensatory cell proliferation
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Figure 1. Apoptosis and Necroptosis Differentially Regulate Dysplasia, Cholestasis, and Liver Injury in Mice with LPC-specific Tak1Deletion
(A) Western blot analysis of whole liver protein extracts from 6-week-oldmale TAK1LPC-KO, TAK1/Casp-8LPC-KO, TAK1LPC-KO/RIP3/, and control littermate mice
(WT) using antibodies against TAK1, RIP3, Caspase-8, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as loading control.
(B) Serum level analysis of AST, ALT, glutamate dehydrogenase (GLDH), total bilirubin, and AP in 6-week-old male mice. Results are shown as mean. Double
asterisks denote p < 0.01 and triple asterisks denote p < 0.001 (n = 8 each genotype).
(C) Representative macroscopic pictures of 6-week-old maleWT, TAK1LPC-KO, TAK1/Casp-8LPC-KO, and TAK1LPC-KO/RIP3/ livers. Small nodular structures are
observed in livers of TAK1LPC-KO and TAK1LPC-KO/RIP3/ mice but not on TAK1/Casp-8LPC-KO livers. Arrows indicate nodules. Additionally, TAK1LPC-KO and
TAK1/Casp-8LPC-KO but not TAK1LPC-KO/RIP3/ livers display a cholestatic, yellow color. The scale bars represent 1 cm.
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upon apoptosis versus necroptosis are a likely cause for the
presence or absence of a sufficient ductular reaction and
cholestasis in TAK1LPC-KO/RIP3/ and TAK1/Casp-8LPC-KO
mice, respectively.
To evaluate the effect of Caspase-8 deletion in LPC, we
further performed serological and histological analyses on
Casp-8LPC-KO mice. This analysis revealed mild liver injury, indi-
cated by elevated serum ALT, AST, and GLDH, but no changes
in the biliary system or infiltration withmyelomonocytic cells (Fig-
ures S1A–S1C). In addition, we tested whether the molecules
Caspase-8 or RIP3 might have limiting effects on LPC prolifera-
tion and performed partial hepatectomy (PH) experiments in
Casp-8LPC-KO mice or mice with constitutive deletion of Rip3
(RIP3/). Whereas WT and RIP3/ animals showed similar
expression levels of cell cycle markers cyclin D1 and PCNA in
western blot and Ki67-expression in immunohistochemical
analysis, Casp-8LPC-KO animals even displayed a slight acceler-
ation in cell-cycle progression (Figures S1D–S1F). This indicates
that the differences in the proliferative response between
TAK1LPC-KO/RIP3/ and TAK1/Casp-8LPC-KO animals were not
caused by direct effects of Caspase-8 or RIP3 on the cell-cycle
machinery, however, suggest that apoptosis but not necroptosis
of LPC represents a strong trigger for compensatory LPC
proliferation.
The kinase TAK1 integrates signals from several upstream li-
gands and regulates various inflammatory and stress-related
signaling pathways (Delaney and Mlodzik, 2006). We therefore
tested whether, besides apoptosis and necroptosis, other
signaling pathways might be involved in hepatitis and chole-
stasis development in Tak1-deficient livers and generated mice
with combined deletions of Tak1 and Caspase-8 in LPC together
with full knockout of Rip3 (TAK1/Casp-8LPC-KO/RIP3/ mice;
Figure S2A). On macroscopic, serological, and histological level,
combined deletions of Caspase-8 and Rip3 completely rescued
hepatitis, liver injury, cholestasis, and biliary ductopenia seen
in TAK1 single mutants (Figures S2B–S2D). This highlights that
apoptosis and necroptosis represent the major pathways medi-
ating the severe phenotype in Tak1-deficient livers. Further, this
argues against significant influences of potential dysregulation of
biliary transporters or structural cell proteins in biliary epithelial
cells in response to Tak1 deletion.
Activation of RIP3 Inhibits Hepatic Tumor Growth
Based on the differential functional relations between apoptotic
versus necroptotic cell death and compensatory LPC prolife-
ration, we next evaluated if RIP3 and Caspase-8 might also
differentially regulate hepatocarcinogenesis. Hence, we exam-
ined the spontaneous phenotype of 25- to 38-week-old animals,
because TAK1 single mutants develop HCC at that age (Better-
mann et al., 2010). Macroscopic analyses of livers confirmed
the presence of hepatic tumors in TAK1LPC-KO mice (Figure 4A).
Surprisingly, TAK1/Casp-8LPC-KO animals did not show any
signs of macroscopically detectable hepatic tumors at this
age. In contrast, TAK1LPC-KO/RIP3/ mice exhibited a massive
hepatic tumor burden already visible on macroscopic level
(Figure 4A). The high hepatic tumor burden in these mice corre-
sponded with a significant increase in the liver-to-body weight
ratio in TAK1LPC-KO/RIP3/ animals compared to TAK1 single
mutants or TAK1/Casp-8 combined mutants (Figure 4B). On
the histological level, we confirmed increased development of
hepatic tumors with histological criteria of HCC in TAK1LPC-KO/
RIP3/ mice by hematoxylin and eosin staining (H&E) staining
and immunohistochemical analysis for collagen-IV expression.
Conversely, no histologically malignant hepatic tumor or pre-
neoplastic lesions could be detected in TAK1/Casp-8LPC-KO
animals (Figures 4C and 4D). Thus, Caspase-8-dependent
apoptosis promotes HCC development in TAK1LPC-KO mice. In
contrast, the higher tumor burden in TAK1LPC-KO/RIP3/ mice
compared to TAK1LPC-KO mice and the absence of hepatic
tumors in TAK1/Casp-8LPC-KO livers exhibiting pure necroptosis
suggest that activation of RIP3 has an inhibitory effect on
tumor growth. Importantly, the fact that the massive tumor
development in TAK1LPC-KO/RIP3/ mice could be completely
abolished by cell-specific ablation of Caspase-8 in LPC
(TAK1/Casp-8LPC-KO/RIP3/ mice) (Figures S2E and S2F)
argues against a significant effect of Rip3 deletion in nonparen-
chymal hepatic cells in the regulation of hepatocarcinogenesis
in TAK1LPC-KO/RIP3/ mice, which have an LPC-specific
knockout of Tak1 but full knockout of Rip3.
The finding that TAK1/Casp-8LPC-KO mice did not develop
any HCC, whereas TAK1LPC-KO/RIP3/ mice showed larger
HCC than TAK1LPC-KO single mutant animals, suggested that
activation of RIP3 controls hepatocarcinogenesis in terms
of the hepatic tumor burden. To test if RIP3 also influences
hepatic tumor biology, HCC samples from TAK1LPC-KO and
TAK1LPC-KO/RIP3/ mice were profiled by qRT-PCR with a 16
gene signature that identifies and stratifies liver tumors accord-
ing to their degree of differentiation and proliferation rate (Cairo
et al., 2008). For control, normal liver samples as well as samples
of aggressive liver tumors from woodchuck hepatitis virus
(WHV)/N-myc2 p53+/deltamice (Renard et al., 2000) were added
to the analysis. Unsupervised analysis of the samples profiled
showed coclustering of nearly all TAK1LPC-KO and TAK1LPC-KO/
RIP3/ tumors (Figure 4E). We also examined expression
of alpha fetoprotein (AFP) and selected oncogenes and tumor
suppressor genes (antigen-presenting cell [APC], p53, E2F
transcription factor 5 [E2F5], cyclin-dependent kinase inhibitor
2A [CDKN2A], cyclin D1, neuroepithelial cell transforming 1
[Net1], FgR, and Jun) in HCC from both mouse lines. Despite
elevated cyclin D1 and APC levels in TAK1LPC-KO/RIP3/
tumors, most other genes examined showed similar transcrip-
tional levels in HCC from TAK1LPC-KO and TAK1LPC-KO/RIP3/
livers (Figure 4F). Together, these findings indicate similar
tumor biology of HCC in both mouse lines, suggesting that
activation of RIP3 in TAK1LPC-KO mice inhibits hepatocarcino-
genesis by a dominant effect on tumor initiation and prolifera-
tion of tumor cells.
RIP3 Controls the Transition from Inflammation
to Cancer by Inhibiting Caspase-8-Induced
Chromosomal Aberrations Associated
with Immortalization of Hepatocytes
To further analyze the functional roles of necroptosis and
apoptosis on hepatocarcinogenesis, we performed array-com-
parative genomic hybridization (aCGH) analyses on histologi-
cally characterized and microdissected HCCs from TAK1LPC-KO
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Figure 2. RIP3-Dependent Necroptosis Mediates Cholestasis and Biliary Ductopenia by Suppressing Caspase-8-Dependent Ductular
Reaction in Livers of Mice with LPC-Specific Tak1 Deletion
(A) Histological (H&E) and immunohistochemical (pancytokeratin, A6) analysis on representative liver sections from 6-week-old male mice. Arrows indicate
necrotic areas. The scale bars represent (from top to bottom) 500 mm, 100 mm, 20 mm, 100 mm, and 50 mm.
(B) Evaluation of necrotic areas from H&E staining. WT (n = 6), TAK1LPC-KO (n = 6), TAK1/Casp-8LPC-KO (n = 6), and TAK1LPC-KO/RIP3/ (n = 5) livers. Results are
shown as mean. The asterisk denotes p < 0.05 and double asterisks denote p < 0.01.
(legend continued on next page)
780 Cell Reports 4, 776–790, August 29, 2013 ª2013 The Authors
and TAK1LPC-KO/RIP3/ mice and areas of disturbed micro-
architecture (histologically not HCC or dysplastic nodules) in
TAK1/Casp-8LPC-KO animals (Figure 5A). As previously shown
for TAK1LPC-KO mice (Bettermann et al., 2010) and corroborated
on three HCCs in this study, TAK1LPC-KO displays large chro-
mosomal amplifications mainly on chromosomes 4, 8, and 13.
Interestingly, amplifications on these chromosomes were also
found in most tumors of TAK1LPC-KO/RIP3/ mice. However,
the majority of TAK1LPC-KO/RIP3/ tumors displayed multiple
additional chromosomal aberrations, of which many were not
found in tumors of most TAK1LPC-KO animals (chromosomes 1,
5–6, 9, and 11–12; Figure 5A; Bettermann et al., 2010). In
contrast, TAK1/Casp-8LPC-KO animals hardly displayed any sig-
nificant chromosomal aberrations in their livers (Figure 5A).
These data suggest that, in chronic hepatitis, apoptosis but not
necroptosis specifically promotes the development of liver
cancer by favoring an environment that drives genetic aberra-
tions. Moreover, necroptosis not only inhibits tumor growth but
also counterbalances the establishment of genetic alterations
in HCC.
The striking pattern of chromosomal aberrations detected in
TAK1LPC-KO and TAK1LPC-KO/RIP3/ tumors but not livers of
TAK1/Casp-8LPC-KO mice prompted us to further investigate if
these genetic changes might withhold a functional role in the
transition from inflammation to cancer (e.g., by driving LPC spe-
cifically resistant to apoptotic cell death). To test this, we isolated
primary hepatocytes from 8-week-old WT, TAK1/Casp-8LPC-KO,
and TAK1LPC-KO/RIP3/ mice, lacking immunohistochemical
and molecular evidence for malignant tumors (data not shown).
Twenty-four hours after isolation, cells were washed carefully
to remove dead cells and then stimulated with recombinant mu-
rine TNF, a treatment that induces cell-death of Tak1-deficient
but not WT hepatocytes, due to their inability to activate nuclear
factor (NF)-kB (Bettermann et al., 2010). Twenty-four hours after
TNF stimulation, TAK1/Casp-8LPC-KO but not WT hepatocytes
lost attachment to the plate and showed morphological signs
of cell death (Figure 5B), indicating that TNF treatment led
to necroptosis of hepatocytes in vitro. Whereas also many
hepatocytes isolated from TAK1LPC-KO/RIP3/ livers showed
morphological signs of cell death, some cells with large nuclei
survived TNF treatment and were collected for preparation of
genomic DNA followed by aCGH analysis for their genetic status.
Strikingly, cells displayed the same pattern of chromosomal
aberrations on chromosomes 4, 8, and 13 as seen previously
in HCC from these animals as well as additional chromosomal
aberrations (Figure 5C). These data provide evidence that
the specific, Caspase-8-dependent pattern of chromosomal ab-
errations on chromosomes 4, 8, and 13 in TAK1LPC-KO/RIP3/
mice arises already at an early step of hepatocarcinogenesis
and is associated with immortalization of hepatocytes in a
setting of Caspase-8-dependent apoptosis. In line with this
hypothesis, we identified focal areas free of Caspase-3 activa-
tion already in 6-week-old TAK1LPC-KO/RIP3/mice (Figure S3),
probably reflecting in vivo a corresponding early step of clonal
immortalization.
Caspase-8-Dependent Apoptosis but Not RIP3-
Dependent Necroptosis Is Associated with a Strong
Inflammatory Response and Liver Fibrosis
We aimed at further characterizing mediators of compensa-
tory LPC proliferation activated in response to Caspase-8
but not RIP3-dependent necroptosis. Liver regeneration was
previously shown to involve the production of inflammatory
cytokines secreted by hepatic macrophages/Kupffer cells (Mi-
chalopoulos and DeFrances, 2005), suggesting that differen-
tial inflammatory responses to LPC apoptosis versus necrop-
tosis might be associated with the differences in LPC
proliferation between both respective mouse lines. Fluores-
cence-activated cell sorting (FACS) analysis revealed stronger
infiltration of myeloid cells and CD4+ and CD8+ T cells but
similar levels of B cells in both TAK1LPC-KO and TAK1LPC-KO/
RIP3/ mice compared with WT and TAK1/Casp-8LPC-KO an-
imals (Figure 6A; data not shown). Immunohistochemical anal-
ysis confirmed a clear trend toward higher numbers of F4/80+
cells in TAK1LPC-KO/RIP3/ mice compared with TAK1/Casp-
8LPC-KO animals (Figure 6B). To further examine expression
levels of cytokines typically secreted by activated macro-
phages, we performed a FACS-based microbeads fluores-
cence assay on liver homogenates, which revealed signifi-
cantly higher protein levels of interleukin (IL)-1a, IL-6, and
IL-10 in TAK1LPC-KO and TAK1LPC-KO/RIP3/ compared to
TAK1/Casp-8LPC-KO animals (Figure 6C), of which IL-1a and
IL-6 represent key cytokines driving compensatory prolifera-
tion and HCC development in response to hepatocyte death
(Maeda et al., 2005; Sakurai et al., 2008). Thus, in contrast
to previous concepts of oncotic necrosis versus necrosis
(Jaeschke and Lemasters, 2003), we show here that LPC
apoptosis rather than necroptosis drives inflammation in
response to chronic injury.
We further tested for the presence of liver fibrosis by Sirius
red stainings on liver slides from 6-week-old WT, TAK1/Casp-
8LPC-KO, and TAK1LPC-KO/RIP3/ mice. This analysis showed
only a slight increase in fibrosis in TAK1/Casp-8LPC-KO livers at
that age, which in turn was significantly lower than seen in
TAK1LPC-KO/RIP3/ animals (Figure S4A). Additional RT-PCR
analysis on whole liver RNA extracts revealed only a trend to-
ward higher levels of TGF-b1 and TGF-b3 in TAK1LPC-KO/RIP3/
mice compared with TAK1/Casp-8LPC-KO livers (Figure S4B).
Whereas levels of active TGF-b ligands might not be fully re-
flected on RNA levels, due to potential differences in cleavage
processes (Dubois et al., 2001), these data suggest that
apoptosis but not necroptosis induces hepatic fibrogenesis
and activation of stellate cells by various profibrogenic and
proinflammatory stimuli.
(C) Statistical quantification of number of bile ducts per mm2 in WT (n = 5), TAK1LPC-KO (n = 4), TAK1/Casp-8LPC-KO (n = 5), and TAK1LPC-KO/RIP3/ (n = 6) livers.
TAK1LPC-KO livers show decreasing of bile ducts, whereas, in TAK1LPC-KO/RIP3/, livers increase the number of bile ducts compared with the other genotypes.
Results are shown as mean. The asterisk denotes p < 0.05, double asterisks denote p < 0.01, and triple asterisks denote p < 0.001.
(D) Statistical analysis of A6+ single-oval cells per mm2 in the respective 6-week-oldmice. Results are shown asmean (n = 4, except for TAK1/Casp-8LPC-KOmice,
where n = 5); *p < 0.05; n.s., not significant.
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Caspase-8-Dependent Apoptosis Drives Compensatory
LPC Proliferation by Activation of JNK in Parenchymal
and Nonparenchymal Liver Cells
We further examined which intracellular signaling pathways
might connect the two different modes of cell death with
activation or inhibition of compensatory proliferation and cancer
development. In Drosophila, activation of Jun-(N)-terminal
kinase (JNK) by the initiator caspase Dronc is driving
apoptosis-induced compensatory proliferation (Huh et al.,
2004; Kondo et al., 2006). Moreover, it was suggested that
JNK activation is part of a nonapoptotic, procarcinogenic
pathway downstream of CD95/Fas/APO-1 (Chen et al., 2010).
Western blot analysis on liver extracts from 6-week-old mice
revealed strong spontaneous phosphorylation and activation of
JNK but not p38a, AKT, or ERK in livers of TAK1LPC-KO/RIP3/
compared with TAK1/Casp-8LPC-KO andWT animals (Figure 7A).
Immunohistochemical staining for the phosphorylated JNK
forms confirmed significantly more phosphorylated JNK (p-
JNK)+ hepatocytes in TAK1LPC-KO/RIP3/ compared to TAK1/
Casp-8LPC-KO and WT animals (Figure 7B). Importantly,
TAK1LPC-KO/RIP3/ livers even displayed significantly more
p-JNK+ hepatocytes than TAK1LPC-KO single knockouts (Fig-
ure 7C). In addition, TAK1LPC-KO/RIP3/ livers showed a sig-
nificantly higher fraction of p-JNK+ liver nonparenchymal cells
(NPC) than all other genotypes, although to a much lower extent
than observed in terms of hepatocytes (Figure S5). Finally, to
functionally evaluate the role of JNK in mediating apoptosis
and compensatory proliferation in TAK1LPC-KO/RIP3/ mice,
we injected TAK1LPC-KO/RIP3/ mice with the well-established
JNK-inhibitor SP600125, which significantly decreased the
amount of Ki67+ cells and lowered cyclin D1 expression when
compared to vehicle-treated animals (Figures 7D, 7E, and 7G).
Additional analysis of cleaved Casp-3+ cells lacked a significant
difference between the two groups (Figures 7D and 7F). These
data suggest that JNK activation represents an important
step in mediating compensatory proliferation downstream of
Caspase-8, whereas, in contrast, RIP3 inhibits the activation of
JNK in livers of TAK1LPC-KO mice.
DISCUSSION
The natural course of chronic hepatic disease is characterized
by a relatively uniform pattern, featuring constant hepatocyte
cell death, inflammation and compensatory hepatocyte pro-
liferation, hepatic fibrogenesis, and ultimately the development
of HCC (Sherman, 2010). Although this sequence has been
known for many years, it has not been well characterized which
exact molecular pathways are regulating the critical transition
from inflammation to cancer, which explains why, up to now,
no nonpathogen-specific chemopreventive strategy has been
developed against HCC in patients with chronic liver disease.
We show that, in a setting of chronic inflammation induced by
LPC-specific deletion of Tak1, RIP3-dependent necroptosis
represents a pathway regulating the consequences of chronic
inflammation in the liver by counteracting against Caspase-8-
dependent compensatory proliferation of hepatocytes, immune
cell activation, hepatic fibrogenesis, and the development of
chromosomal aberrations leading to hepatocarcinogenesis.
Studies have demonstrated that necroptosis serves as an
alternative when caspase-dependent apoptosis is inhibited or
absent (Han et al., 2011). Of note, our findings indicated the
simultaneous activation of both apoptosis and necroptosis in
livers of TAK1LPC-KO animals, mediating either carcinogenesis
or cholestasis. Tak1 deletion in LPC results in inhibition of
NF-kB activation (Bettermann et al., 2010), which in turn leads
to increased sensitivity against spontaneous apoptosis, as
demonstrated in mice with conditional deletion of the NF-kB-
activating kinase subunit NF-kB essential modulator (NEMO)
(Luedde et al., 2007; Wunderlich et al., 2008). On the other
hand, it was recently shown in vitro that TAK1 can prevent
necroptosis by inhibiting the action of RIP1/RIP3 complexes
(Vanlangenakker et al., 2011), supporting the hypothesis that
TAK1 inhibits activation of both programmed cell death path-
ways in LPC. Based on our findings, it is likely that, in the
absence of Rip3, LPC are ‘‘forced’’ to die by apoptosis, leading
to increased inflammation and a higher tumor burden in
TAK1LPC-KO/RIP3/ mice. TAK1 is therefore a master regulator
of liver cell death induced, for example, by the cytokines TNF-a
and TGF-b (Inokuchi et al., 2010; Yang et al., 2013). Moreover,
the fact that cultured primary TAK1-deficient hepatocytes
show a decreased survival in serum-free conditions (Bettermann
et al., 2010) indicates also an intrinsic component of cell death
in these cells.
As stated before, livers with conditional deletion of Tak1 in
LPC show defective NF-kB activation and—similar to other
mouse models with genetic defects in the NF-kB pathway
Figure 3. Apoptosis but Not Necroptosis Induces Strong Compensatory Proliferation of Hepatocytes and Biliary Epithelial Cells upon
Chronic Liver Injury
(A) Immunohistochemical analysis on representative liver paraffin sections from 6-week-old male mice of the indicated genotypes. Upper panel: cleaved (cl.)
Caspase-3 staining. Lower panel: Ki67 staining. The scale bars represent 50 mm.
(B) Statistical analysis of Ki67+ and cl. Casp-3+ hepatocytes. Results are shown as mean (cl. Casp-3 staining: WT [n = 5]; TAK1LPC-KO [n = 8]; TAK1/Casp-8LPC-KO
[n = 5]; TAK1LPC-KO/RIP3/ [n = 6] and Ki67 staining:WT [n = 5]; TAK1LPC-KO [n = 8]; TAK1/Casp-8LPC-KO [n = 5]; TAK1LPC-KO/RIP3/ [n = 5]). The asterisk denotes
p < 0.05, double asterisks denote p < 0.01, and triple asterisks denote p < 0.001.
(C)Western blot analysis of whole liver protein extracts from 6-week-oldmale TAK1LPC-KO, TAK1/Casp-8LPC-KO, TAK1LPC-KO/RIP3/, and control littermatemice
(WT) using antibodies against PCNA, CycD1, cl. Casp-3, and GAPDH as loading control.
(D) Double stainings of pancytokeratin with Ki67 (upper panel; pancytokeratin is stained pink, Ki67 is stained brown) or cl. Casp-3 (lower panel; pancytokeratin is
stained pink, cl. Casp-3 is stained brown). Arrowheads indicate double-stained cells.
(E) Statistical analysis of double-stained pancytokeratin+ and Ki67+ biliary epithelial cells in the respective 6-week-old mice. Results are shown as mean (n = 5);
*p < 0.05; n.s., not significant.
(F) Statistical analysis of double-stained pancytokeratin+ and cl. Casp-3+ biliary epithelial cells in the respective 6-week-old mice. Results are shown as mean
(n = 5). Double asterisks denote p < 0.01.
See also Figures S1 and S2.
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(Luedde and Schwabe, 2011)—are therefore extremely sensitive
to LPS/TNF-induced liver failure and LPC apoptosis (Bettermann
et al., 2010). However, we show that, already in livers of
young TAK1LPC-KO/RIP3/ mice, a fraction of hepatocytes
gained resistance toward TNF-dependent apoptosis, despite
the absence of Tak1, and showed a pattern of chromosomal
aberrations that was later found in HCC from these mice. These
findings indicate that the specific chromosomal aberration
pattern on chromosomes 4, 8, and 13 is not particularly acquired
in late stages of tumor promotion but represents a fundamental
genetic event involved in the earliest steps of tumor initiation in
chronic inflammation in TAK1LPC-KO mice. The exact nature of
these genetic abnormalities is currently not clear, but they might
lead to resistance toward apoptosis through the amplification of
antiapoptotic genes or defective transcription of genes driving
apoptosis in Tak1-deficient cells. Thus, further cytogenetic or
transcriptomic analysis of TAK1LPC-KO-HCCs might reveal novel
candidate molecules or micro-RNAs involved in the regulation of
apoptosis in Tak1-deficient cells. In addition, these findings
might shed new light on the enigmatic processes of how chronic
inflammation leads to genetic alterations in human patients with
chronic liver disease.
In original definitions of apoptosis detected, for example,
during organ development, intracellular contents are not
released, and a consequent inflammatory response fails to
develop, whereas the typical oncotic necrosis induced, for
example, by ischemia is associated with release of cellular con-
tents, initiating an inflammatory response (Jaeschke and Le-
masters, 2003). By our genetic approach, we demonstrated
that LPC apoptosis occurring in a pathological condition repre-
sents a much stronger trigger for inflammation and subsequent
liver fibrosis than necroptosis. Given the concordant regula-
tions between inflammation and fibrosis in TAK1LPC-KO/RIP3/
versus TAK1/Casp-8LPC-KO livers, further comparative analyses
in serum and cell culture supernatants between these two
mouse models might allow the identification of novel paracrine
factors linking apoptotic cell death of LPC with immune activa-
tion and hepatic fibrosis. Moreover, our data show that
apoptosis and necroptosis have a fundamentally opposing
function in regulating compensatory cell proliferation of sur-
rounding cells in vivo. Whereas Caspase-8-dependent
apoptosis in TAK1LPC-KO/RIP3/mice led to a strong biliary re-
action and expansion of bile ducts and oval cells in young an-
imals, the ‘‘hyporegenerative’’ nature of necroptosis resulted in
a disturbed biliary homeostasis and cholestasis. Interestingly,
the intrahepatic number of bile ducts was significantly lower
in TAK1LPC-KO livers with combined presence of apoptosis
and necroptosis than in TAK1/Casp-8LPC-KO mice showing
only necroptosis. This indicates that the complex biliary archi-
tecture might be even more sensitive to the onset of necropto-
sis in a setting with constant massive hepatocyte regeneration
when apoptosis is simultaneously present. Whereas the mech-
anisms and functional implications of biliary ductular reactions
are presently not well understood, the TAK1 model might shed
new light on these processes and on paracrine mediators, link-
ing cell death with differentiation and proliferation of bile duct
cells.
Our data suggest that the MAP kinase JNK plays a critical role
in the mediation of compensatory LPC proliferation in response
to apoptosis. The function of JNK in liver cancer development
was previously studied mainly in the model of diethylnitros-
amine-dependent hepatocarcinogenesis, resulting in conflicting
results with regards to a tumor promoting versus a tumor sup-
pressive function in hepatocytes (Das et al., 2011; Sakurai
et al., 2006). However, the proregenerative and presumably
procarcinogenic function of JNK suggested by our data might
depend on the presence of chronic inflammation preceding
malignant transformation of hepatocytes, a situation present
in most patients developing liver cancer (Llovet et al., 2003;
Vucur et al., 2010). Moreover, our findings suggest that JNK
not only acts upstream of Caspase-8 to control apoptosis, as
previously shown (Chang et al., 2006), but is also regulated
in response to Caspase-8, because ablation of Caspase-8 sig-
nificantly dampened JNK activation in Tak1-deficient livers.
Whether Caspase-8 controls JNK activation by cell-intrinsic
signals (e.g., alternative MAP-3 kinases and their interaction
with TNF receptor-associated factor or RIP modules [Karin
and Gallagher, 2009]), or by cell-extrinsic mechanisms is pres-
ently unclear. Again, it is possible that, during carcinogenesis,
certain genetic aberrations resulting in a condition similar to
‘‘undead cells‘‘ might promote JNK-dependent proliferation
in response to apoptosis, a concept previously suggested in
Figure 4. Apoptosis Promotes Hepatocarcinogenesis, whereas Necroptosis Inhibits Cancer Growth in Livers of TAK1LPC-KO Mice
(A) Representative macroscopic pictures of 33- to 35-week-old male WT (from left to the right), TAK1LPC-KO, TAK1/Casp-8LPC-KO, and TAK1LPC-KO/RIP3/ livers.
The scale bars represent 1 cm.
(B) Body-weight ratio of 25- to 38-week-old male WT (n = 6), TAK1LPC-KO (n = 4), TAK1/Casp-8LPC-KO (n = 4), and TAK1LPC-KO/RIP3/ (n = 6) mice. The asterisk
denotes p < 0.05 and double asterisks denote p < 0.01.
(C) Evaluation of tumor areas from H&E staining. TAK1LPC-KO (n = 6), TAK1/Casp-8LPC-KO (n = 6), and TAK1LPC-KO/RIP3/ (n = 9) livers. Results are shown as
mean. Double asterisks denote p < 0.01.
(D) Representative slides from livers of a 28-week-old WT, TAK1LPC-KO, TAK1/Casp-8LPC-KO, and TAK1LPC-KO/RIP3/mouse stained with H&E and collagen IV.
Tumor borders are indicated by a dashed line.
(E) Sixteen gene profile analysis (heat map) of HCC derived from TAK1LPC-KO and TAK1LPC-KO/RIP3/ livers (25- to 38-week-old mice). HCC were compared
to aggressive liver tumors from WHV/N-myc2 p53+/delta mice and control WT mice. Below the dashed line, genes indicating a proliferative phenotype are
listed, whereas genes above the dashed white line represent a less proliferative, more differentiated phenotype. HCC derived from TAK1LPC-KO and TAK1LPC-KO/
RIP3/ livers show a similar proliferating phenotype.
(F) Relative (rel.) messenger RNA (mRNA) expression of the indicated oncogenes/tumor suppressor genes (APC, AFP, tumor protein p53 [p53], E2F5, CDKN2A,
cyclin D1, Net1, Gardner-Rasheed feline sarcoma viral oncogene homolog [FgR], Jun oncogene [Jun]) of HCCderived from 25- to 38-week-old TAK1LPC-KO (n = 5)
and TAK1LPC-KO/RIP3/ (n = 14) mice as well as normal tissue from littermate control (WT) (n = 5). The asterisk denotes p < 0.05 and double asterisks denote
p < 0.01.
See also Figure S2.
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Drosophila (Ryoo and Bergmann, 2012). Interestingly, JNK
activation was strongly increased in LPC (28-fold increase
compared to WT) and less pronounced in NPC of TAK1LPC-KO/
RIP3/ mice (1.18-fold increase compared to WT), favoring a
parenchymal function of JNK. Moreover, it is presently unclear
which specific factors released by apoptotic but not necroptotic
parenchymal cells are involved in the activation process of
immune cells, induction of chromosomal aberrations, and HCC
development, but these processes might involve damage-
associated molecular patterns/alarmins, such as high-mobility
group protein 1, HMGN1, HSP60/HSP70, or b-defensins (Chan
et al., 2012).
Figure 5. RIP3 Controls the Transition from Inflammation to Cancer by Inhibiting Chromosomal Aberrations Associated with Resistance of
Hepatocytes toward Caspase-8-Dependent Apoptosis
(A) Summary of CGH analysis from three different hepatic tumors of three TAK1LPC-KO mice, nine different tumors of nine TAK1LPC-KO/RIP3/ mice, and five
samples of areas with disturbed histological architecture (no obvious tumors) from five TAK1/Casp-8LPC-KO mice. The q-arm of each chromosome is shown and
chromosome numbers are indicated. Dark horizontal bars within the symbolized chromosomes represent G bands. Chromosomal deletions are indicated in blue
and amplifications in red. Individual mice are labeled by horizontal collared bars.
(B) Microscopic pictures of TNF-a-treated primary hepatocytes from WT, TAK1/Casp-8LPC-KO, and TAK1LPC-KO/RIP3/ mice.
(C) Summary of CGH analysis from untreated and survived TNF-a-treated primary hepatocytes from TAK1LPC-KO/RIP3/mice. Chromosomal amplifications and
deletions are indicated in red and blue, respectively. IFN, interferon.
See also Figure S3.
Figure 6. Differential Inductions of Inflammatory Responses by Apoptosis and Necroptosis in Tak1-Deficient Livers
(A) FACS-based analysis of infiltrating myeloid cells and T cells into liver tissue of TAK1LPC-KO, TAK1/Casp-8LPC-KO, and TAK1LPC-KO/RIP3/ mice. Results are
shown as mean; error bars indicate SEM n = 5; *p < 0.05, **p < 0.01.
(B) Immunohistochemistry of liver paraffin sections and densitometric analysis for F4/80 in TAK1LPC-KO, TAK1/Casp-8LPC-KO, TAK1LPC-KO/RIP3/, andWT livers.
Results are shown as mean; n = 5 for WT and TAK1/Casp-8LPC-KO; n = 6 for TAK1LPC-KO/RIP3/. The scale bar represents 50 mm.
(C) FACS-based microbeads fluorescence assay for cytokine expression in liver protein homogenates. Results are shown as mean. n = 8 for WT and TAK1LPC-KO
and n = 7 for TAK1/Casp-8LPC-KO and TAK1LPC-KO/RIP3/; *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S4.
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Our findings indicate that mechanisms regulating the bal-
ance between necroptosis and apoptosis might be of great
relevance for human liver disease and are in line with the clin-
ical observation that an overbalance of necrotic over apoptotic
hepatic cell death in acute liver failure is associated with a
decreased regenerative capacity of the liver as a basis for a
worse outcome (Bantel and Schulze-Osthoff, 2012). In addi-
tion, RIP3 mediates ethanol-induced liver injury (Roychowd-
hury et al., 2013). Thus, inhibition of RIP3-dependent or inde-
pendent necrotic signaling pathways by novel molecular
inhibitors might represent a promising approach in these set-
tings. In addition, our findings indicate that LPC apoptosis
plays a dominant role for the progression of chronic liver injury
to liver cancer. Therefore, molecular inhibitors of caspases
recently studied in patients with chronic hepatitis C virus infec-
tion (Pockros et al., 2007) or nonalcoholic steatohepatitis (Rat-
ziu et al., 2012) might be especially useful in preventing the
transition from chronic inflammation to hepatocarcinogenesis.
Finally, inflammation is not only driving hepatocarcinogenesis
but also the development of, for example, cancer of the colon
(Greten et al., 2004), pancreas (Guerra et al., 2007), lung (Ta-
kahashi et al., 2010), or skin (Andreu et al., 2010). Hence,
further studies in other cellular systems and organs are
needed to examine if the paradigmatic functions of RIP3
versus Caspase-8 in regulating cellular compensatory prolifer-
ation and tumor growth in the liver represent a general princi-
ple in the control of epithelial cell homeostasis and cancer
development.
Figure 7. RIP3 Limits Compensatory Cell Proliferation through Inhibition of Caspase-8-Dependent JNK Activation
(A) Western blot analysis of whole liver-protein extracts from 6-week-oldmale TAK1LPC-KO, TAK1/Casp-8LPC-KO, TAK1LPC-KO/RIP3/, and control littermatemice
(WT) using antibodies against the phosphorylated and active form of JNK, AKT, p38, ERK, and GAPDH as loading control.
(B) Immunohistochemistry of representative liver paraffin sections for phospho-JNK in 6-week-old mice. The scale bars represent 100 mm and 50 mm.
(C) Statistical analysis of p-JNK+ hepatocytes. Results are shown as mean. WT (n = 4), TAK1LPC-KO (n = 5), TAK1/Casp-8LPC-KO (n = 4), and TAK1LPC-KO/RIP3/
(n = 5) mice; *p < 0.0.
(D) Representative immunohistochemical analysis for Ki67 and cl. Casp-3 in 6-week-old mice treated with the JNK inhibitor SP600125 or vehicle as control.
(E) Statistical analysis of Ki67+ hepatocytes in animals treated with SP600125 compared to vehicle control-treated animals. Results are shown as mean. (n = 4);
*p < 0.05.
(F) Statistical analysis of cl. Casp-3+ hepatocytes in TAK1LPC-KO/RIP3/ treated with SP600125 compared to vehicle control-treated mice. Results are shown
as mean. (n = 4).
(G) Western blot analysis of whole liver protein extracts from 6-week-old male TAK1LPC-KO/RIP3/ and WT mice treated with SP600125 or vehicle using
antibodies against CycD1 and GAPDH as loading control.
See also Figure S5.
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EXPERIMENTAL PROCEDURES
Generation of Conditional Knockout Mice and Animal Experiments
Mice carrying loxP-site-flanked (floxed) alleles of the Tak1 gene Map3k7
(Tak1fl) (Sato et al., 2005) or Caspase-8 (Caspase-8fl) (Salmena et al., 2003)
were crossed to Alfp-Cre transgenic mice (Kellendonk et al., 2000) to
generate a LPC-specific knockout of the respective genes (TAK1LPC-KO,
Caspase-8LPC-KO). Mice with constitutive deletion of RIP3 (RIP3/) were
described before (Newton et al., 2004). Mice with combined conditional
knockouts of Map3k7 and constitutive ablation of Rip3 (TAK1LPC-KO/RIP3/)
as well as combined conditional ablations of Map3k7 and Caspase-8 (TAK1/
Casp8LPC-KO) as well as mice with constitutive ablations of Rip3 and condi-
tional ablations of Map3k7 and Caspase-8 in LPC (TAK1/Casp-8LPC-KO/
RIP3/) were generated by intercrossing the respective lines. In all experi-
ments, littermates carrying the respective loxP-flanked alleles but lacking
expression of Cre recombinase were used as WT controls. Mice were bred
on a mixed C57/BL6 - SV129Ola genetic background. Only sex-matched
animals were compared. All animal experiments were approved by the Federal
Ministry for Nature, Environment and Consumers’ Protection of the state of
North Rhine-Westphalia and were performed in accordance to the respective
national, federal, and institutional regulations.
Surgery (partial hepatectomy) was performed on male mice of 6–8 weeks
of age. Mice were anesthetized by isoflurane inhalation and treated with
buprenorphine for analgesia. The abdominal cavity was opened by a midline
laparotomy. The right median lobe, left median lobe, and left lateral lobe
were identified and individually ligated. Mice were sacrificed at the indicated
time points. Intraperitoneal injection of 15 ml SP600125 (1 mg/ABSOURCE)
or vehicle (DMSO) was performed twice a day over 4 days on male mice of
5 weeks of age. Mice were sacrificed 3 hr after the last injection.
Statistics
Data were analyzed using PRISM software (GraphPad Software) and are
expressed as mean. Statistical significance between experimental groups
was assessed using an unpaired two-sample t test or Mann-Whitney test.
Further description of the Experimental Procedures is included within the
Supplemental Information (Extended Experimental Procedures).
ACCESSION NUMBERS
The aCGH data have been deposited into the ArrayExpress database under
accession number E-MTAB-1559 (http://www.ebi.ac.uk/arrayexpress/).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at http://dx.doi.org/
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